Long-term safety profile of tolvaptan in autosomal dominant polycystic kidney disease patients: TEMPO Extension Japan Trial [Corrigendum]

• Main Authors: Muto S, Okada T, Yasuda M, Tsubouchi H, Nakajima K, Horie S
• Format: Article
• Language: English
• Published: Dove Medical Press 2018-07-01
• Series: Drug, Healthcare and Patient Safety
• Online Access: https://www.dovepress.com/corrigendumlong-term-safety-profile-of-tolvaptan-in-autosomal-dominant-peer-reviewed-article-DHPS

Muto S, Okada T, Yasuda M, et al. Drug Healthc Patient Saf. 2017;9:93–104.On page 97, ‘Discussion’ section, lines 10–13, left column, the sentence: ‘Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (24.0%), while those who continued on tolvaptan treatment discontinued at a much lower rate (11.8%)’ should read: ‘Similarly, placebo patients who crossed over onto active treatment discontinued at a similar rate (26.0%), while those who continued on tolvaptan treatment discontinued at a much lower rate (10.6%)’. On page 101, Figure 6, the number of patients of ‘Completed trial’ in the TEMPO Extension Japan trial should be revised from ‘n=75’ to ‘n=76’, and ‘Withdrawal rate’ should also be revised from ‘11.8%’ to ‘10.6%’ in the allocated to tolvaptan in TEMPO 3:4 trial. The number of patients of ‘Completed trial’ in TEMPO Extension Japan trial should be revised from ‘n=38’ to ‘n=37’, and ‘Withdrawal rate’ should also be revised from ‘24.0%’ to ‘26.0%’ in the allocated to placebo in TEMPO 3:4 trial.Read the original article.